Dexcom

NASDAQ: DXCM

Stock price

76.35 USD

(+Infinity%) NaN day

By default your notes are visible only to you.

54.1

52-week range

89.9

76.35

Your model inputs

Required return / cost of capital
%
FCFF terminal growth rate
%

Your fair value & Margin of safety

To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

Forecast:

Valuation

Free Cash Flow Yield

Help
FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per shareLearn more

4.7 %

Dividend Yield TTM

-

Market cap $

$ 29,461

Price / Earnings TTM

Help
P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per shareLearn more

32.6

Price / Book TTM

9.9

PEG TTM

Help
Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rateLearn more

0.7

Earnings growth and return

LTM

5YR

10YR

Total return (price & dividends)

(8.4) %

(31.6) %

285 %

Free cash flow per share growth

73.8 %

274.6 %

5,300.9 %

Earnings per share growth

47.2 %

64.6 %

1,261.1 %

Founded: 1,999

Employees: 10,200

Business Summary:DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

Fair Value Reference Estimate

Latest Earnings Call Takeaways

Annual Reports, Presentations And IR Contacts

Go to the website

Dexcom — Financial Overview, Stock Price, Market Cap

Dexcom is a company. Founded in 1999. As of July 14, 2026, the company's market capitalization is $29461401794 with a current stock price of $76.35.